Mechanism of dihydrogen cleavage by high-valent metal oxo compounds: experimental and computational studies.

The oxidation of dihydrogen by metal tetraoxo compounds was investigated. Kinetic measurements of the oxidations of H(2) by MnO(4)(-) and RuO(4), performed by UV-vis spectroscopy, showed these reactions to be quite rapid at 25 degrees C (k(1) approximately (3-6) x 10(-2) M(-1) s(-1)). Rates measured for H(2) oxidation by MnO(4)(-) in aqueous solution (using KMnO(4)) and in chlorobenzene (using (n)Bu(4)NMnO(4)) revealed only a minor solvent effect on the reaction rate. Substantial kinetic isotope effects [(k(H)2/k(D)2 = 3.8(2) (MnO(4)(-), aq), 4.5(5) (MnO(4)(-), C(6)H(5)Cl soln), and 1.8(6) (RuO(4), CCl(4) soln)] indicated that H-H bond cleavage is rate determining and that the mechanism of dihydrogen cleavage is likely similar in aqueous and organic solutions. Third-row transition-metal oxo compounds, such as OsO(4), ReO(4)(-), and MeReO(3), were found to be completely unreactive toward H(2). Experiments were performed to probe for a catalytic hydrogen/deuterium exchange between D(2) and H(2)O as possible evidence of dihydrogen sigma-complex intermediates, but no H/D exchange was observed in the presence of various metal oxo compounds at various pH values. In addition, no inhibition of RuO(4)-catalyzed hydrocarbon oxidation by H(2) was observed. On the basis of the available evidence, a concerted mechanism for the cleavage of H(2) by metal tetraoxo compounds is proposed. Theoretical models were developed for pertinent MnO(4)(-) + H(2) transition states using density functional theory in order to differentiate between concerted [2 + 2] and [3 + 2] scissions of H(2). The density functional theory calculations strongly favor the [3 + 2] mechanism and show that the H(2) cleavage shares some mechanistic features with related hydrocarbon oxidation reactions. The calculated activation energy for the [3 + 2] pathway (DeltaH(++) = 15.4 kcal mol(-1)) is within 2 kcal mol(-1) of the experimental value.

The RS-.HSR Hydrogen Bond: acidities of alpha,omega-dithiols and electron affinities of their monoradicals.

Gas-phase acidities (deltaGo(acid)) have been measured for 1,2-ethanedithiol, 1,3-propanedithiol, and 1,4-butanedithiol, using a Fourier transform ion cyclotron resonance (FT-ICR) mass spectrometer. Adiabatic electron affinities (EAs) of the thiolate monoradicals of these compounds were assigned from electron photodetachment spectra of their corresponding thiolate monoanions, acquired using a cw-ICR. The dithiols exhibit enhanced acidities (up to 8.7 kcal/mol in deltaGo(acid)) and greater EAs (up to 6.7 kcal/mol) than analogous monothiol species. These differences are attributed to an intramolecular RS-.HSR hydrogen bond in the thiolate anion. Considerations of the RO-.HOR hydrogen bond in monoanions of alpha,omega-diols and in the [CH(3)O-.HOCH(3)] complex anion suggest that the RS-.HSR hydrogen bond provides up to 9 kcal/mol extra stabilization.

Activin A release into the circulation is an early event in systemic inflammation and precedes the release of follistatin.

Recent evidence suggests a role for activin A, and its binding protein, follistatin, in inflammatory pathways. However, whether activin is released systemically during inflammation is not known. In this study, a release of activin A into the circulation occurred in sheep within 1 hour of injection of lipopolysaccharide. This rapid peak in activin A preceded the release of the key inflammatory cytokines, tumor necrosis factor-alpha and interleukin-6. Follistatin release into the circulation occurred some 4 hours after the peak of activin A and continued out to 24 hours from lipopolysaccharide treatment. These data are the first to document a circulatory response of activin A to an inflammatory stimulus, and together with previous findings, suggest that activin A may have both pro- and anti-inflammatory actions in regulating cytokine-driven pathways.

Photochemistry. Twist and fluoresce.

Catalytic antibodies, or artificial enzymes, act as catalysts by lowering the energy of the transition state of a reaction. In his Perspective, Brauman highlights the study by Simeonov et al., who have applied similar principles to photochemical processes and shown that intense fluorescence can be achieved. The approach provides a way of measuring internal molecular motion within the antibody on a very fast time scale. Fluorescent antibodies may find applications in immunochemistry, histological assays, and genomic studies.

A sensitive and specific in vitro bioassay for activin using a mouse plasmacytoma cell line, MPC-11.

A new in vitro bioassay for activin was developed using the mouse plasmacytoma cell line, MPC-11. Human recombinant (hr) activin A dose-dependently inhibited the proliferation of these cells, whereas a range of other factors, including inhibin, follistatin and transforming growth factor-beta1, -beta2 and -beta3 had no effect. Conditioned medium containing activin B induced an inhibition similar to hr-activin A. The inhibitory influence of activin A could be blocked by follistatin, but not by hr-inhibin A. This bioassay had a sensitivity for activin A of around 0.4 ng/ml, an ED50 response of 3.5 ng/ml, and an intra-assay coefficient of variation of <11%. It offers substantial advantages over existing in vitro activin bioassays in terms of ease of use, specificity and throughput. The utility of the MPC-11 bioassay was demonstrated in the purification of activin from amniotic fluid, where an almost identical profile of bioactive activin A was detected compared with the pituitary cell bioassay of activin. Bioactive activin could also be detected in unpurified ovine allantoic and amniotic fluids and bovine follicular fluid. Measuring activin in untreated and heat-treated human sera or seminal plasma was hampered by a non-specific inhibitory effect, so that several serum samples did not run parallel with the hr-activin A standard. This inhibitory effect by serum could not be overcome by addition of follistatin, suggesting it is not activin-like bioactivity. This new bioassay for activin demonstrates widespread applicability for monitoring of purified or partially purified samples during purification procedures, bioactivity measurements, receptor-binding studies and assays of cell culture medium.

Activin A regulates growth and acute phase proteins in the human liver cell line, HepG2.

Activin, and its binding protein, follistatin, are up-regulated by mediators of inflammation, and recent studies have demonstrated that activin A can block the activity of the key inflammatory cytokine, interleukin-6 (IL-6). These findings thereby implicate activin and follistatin in the control of the inflammatory cascade. In this study, interactions between interleukin-1beta (IL-1beta), IL-6 and activin were examined the human liver cell line, HepG2, for their effect on cell proliferation and the production of the acute phase proteins, haptoglobin and alpha1-acid glycoprotein (alpha1-AGP). IL-1beta and activin A, but not IL-6, inhibited the proliferation of HepG2 cells. Activin A together with IL-1beta caused a greater inhibition of proliferation than either factor alone, and the inhibitory effects of activin A were blocked by the addition of follistatin to the cultures. Activin A alone inhibited the production of haptoglobin but did not affect alpha1-AGP concentrations. However, activin A suppressed the stimulatory effects of IL-6 on the production of both haptoglobin and alpha1-AGP. Production of follistatin by HepG2 cells was stimulated by activin A, but was inhibited by both IL-1beta and IL-6, indicating a complex regulatory loop is operable to modulate the effects of activin A during inflammation. Taken together, these data suggest that activin A interacts with IL-1beta and IL-6 to regulate and coordinate the production of acute phase proteins during an inflammatory episode.

Rapid reduction and removal of HDL- but not LDL-associated cholesteryl ester hydroperoxides by rat liver perfused in situ.

To test whether high-density lipoproteins (HDL) could aid in the removal in vivo of potentially atherogenic oxidized lipids, we perfused rat liver in situ with buffer supplemented with isolated human HDL containing small amounts of cholesteryl linoleate hydro(pero)xides [CH18:2-O(O)H]. Perfusion resulted in the rapid removal of Ch18:2-O(O)H from HDL with a half-life (t1/2)of 11.4 min., faster than that of unoxidized cholesteryl linoleate, and dependent of the presence of the liver. In addition, the liver enhanced the reduction of Ch18:2-OOH associated with HDL remaining in the perfusate buffer. Perfusion resulted in the release of a hepatic activity that enhanced the reduction of HDL-associated CH18:2-OOH and was resistant to heat treatment. In contrast with the situation with HDL, low-density lipoprotein (LDL)-associated CH18:2-O(O)H were neither removed nor reduced by perfused rat liver within the time course studied, in support of a possible role for HDL in the detoxification of circulating lipid hydroperoxides in vivo.

Regioselective and enantioselective epoxidation catalyzed by metalloporphyrins.

Recent progress in regioselective and enantioselective epoxidations catalyzed by metalloporphyrins is discussed here, with an explanation of the biomimetic antecedents of this area and its relevance to synthetic applications. Classification of the catalysts that have been studied allows useful conclusions to be drawn about the development of this field. In particular, both the most promising biomimetic and practical catalysts have arisen from systems that can be systematically modified by convenient synthetic methodology.